Long-term follow-up of patients with narcolepsy-cataplexy treated with sodium oxybate (Xyrem)

Clinical Neuropharmacology

Volumn 34, Issue 1, 2011, Pages 1-4

  Alshaikh, Mashael K ^a   Gacuan, Divine ^a   George, Smitha ^a   Sharif, Munir ^a   Bahammam, Ahmed S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

cataplexy; follow up; narcolepsy; sleep architecture; sodium oxybate; Xyrem

Indexed keywords

OXYBATE SODIUM;

ADOLESCENT; ADULT; AGED; AROUSAL; ARTICLE; CASE REPORT; CATAPLEXY; CHILD; CONVULSION; DAYTIME SOMNOLENCE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG TOLERABILITY; ENURESIS; EPWORTH SLEEPINESS SCALE; EVENING DOSAGE; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; LATENT PERIOD; LONG TERM CARE; MALE; MAXIMUM PERMISSIBLE DOSE; NARCOLEPSY; NAUSEA; PARASOMNIA; PARESTHESIA; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; SCHOOL CHILD; SLEEP APNEA SYNDROME; SLEEP STAGE; SLOW WAVE SLEEP; SNORING; VOMITING;

ADOLESCENT; ADULT; AGED; CATAPLEXY; CHILD; CONTINUOUS POSITIVE AIRWAY PRESSURE; FEMALE; HALLUCINATIONS; HUMANS; MALE; NARCOLEPSY; POLYSOMNOGRAPHY; SLEEP; SLEEP APNEA, OBSTRUCTIVE; SLEEP PARALYSIS; SODIUM OXYBATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79551608893     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318203d415     Document Type: Article

References (25)

1. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007;369(9560):499-511.
2. BaHammam AS, Alenezi AM. Narcolepsy in Saudi Arabia. Demographic and clinical perspective of an under-recognized disorder. Saudi Med J 2006;27(9):1352-1357.
3. Silber MH, Krahn LE, Olson EJ, et al. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002;25(2):197-202.
4. The U.S. Xyremâ Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25(1):42-49.
5. Owen RT. Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy. Drugs Today (Barc) 2008;44(3):197-204.
6. Mohsenin V Narcolepsy\master of disguise: evidence-based recommendations for management. Postgrad Med 2009;121(3):99-104.
7. Wang YG, Swick TJ, Carter LP, et al. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med 2009;5(4):365-371.
8. Zvosec DL, Smith SW, Hall BJ. Three deaths associated with use of Xyrem. Sleep Med 2009;10(4):490M493
9. American Academy of Sleep Medicine. International Classification ofSleep Disorders, 2nd edition: Diagnostic and Coding Manual. Westchester, IL: American Academy of Sleep Medicine; 2005.
10. Rechtschaffen A, Kales A, eds. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. NIH publication #204. Washington, DC: US Government Printing Office; 1968.
11. ASDA Atlas Task Force. EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992;15(2):173-184.
12. Thorpy MJ. The clinical use of the Multiple Sleep Latency Test. The Standards of Practice Committee of the American Sleep Disorders Association. Sleep 1992;15(3):268-276.
13. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14(6):540-545.
14. Huang YS, Guilleminault C Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. Pediatr Neurol 2009;41(1):9-16.
15. Murali H, Kotagal S. Offlabel treatment of severe childhood narcolepsy-cataplexy with sodium oxybate. Sleep 2006;29(8):1025-1029.
16. Ondo WG, Perkins T, Swick T, et al. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol 2008;65(10):1337-1340.
17. Mason PE, Kerns WP 2nd. Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg Med 2002;9(7):730-739.
18. Sansa G, Iranzo A, Santamaria J. Obstructive sleep apnea in narcolepsy. Sleep Med 2010;11(1):93-95.
19. Seeck-Hirschner M, Baier PC, von Freier A, et al. Increase in sleep-related breathing disturbances after treatment with sodium oxybate in patients with narcolepsy and mild obstructive sleep apnea syndrome: two case reports. Sleep Med 2009;10(1):154-155.
20. George CF, Feldman N, Inhaber N, et al. A safety trial of sodium oxybate in patients with obstructive sleep apnea: acute effects on sleep-disordered breathing. Sleep Med 2010;11(1):38-42.
21. Baker TL, Guilleminault C, Nino-Murcia G, et al. Comparative polysomnographic study of narcolepsy and idiopathic central nervous system hypersomnia. Sleep 1986;9(1 Pt 2):232-242.
22. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6(5):415-421.
23. Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1(4):391-397.
24. Schuld A, Hebebrand J, Geller F, et al. Increased body-mass index in patients with narcolepsy. Lancet 2000;355(9211):1274-1275.
25. Husain AM, Ristanovic RK, Bogan RK. Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med 2009;10(6):661-663.